APO Research
Talk to an analyst

APO RESEARCH · REPORT

KRAS G12C Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global KRAS G12C Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025175 pages

Choose your research edition.

Industry ResearchKRAS G12C Inhibitors Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal KRAS G12C Inhibitors Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal KRAS G12C Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal KRAS G12C Inhibitors Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal KRAS G12C Inhibitors Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global KRAS G12C Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for KRAS G12C Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for KRAS G12C Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for KRAS G12C Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for KRAS G12C Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of KRAS G12C Inhibitors include Innovent Biologics, Inc., Genfleet Therapeutics (Shanghai), Inc., Amgen and Mirati Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global KRAS G12C Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of KRAS G12C Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents KRAS G12C Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the KRAS G12C Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

KRAS G12C Inhibitors Segment by Company

Innovent Biologics, Inc.

Genfleet Therapeutics (Shanghai), Inc.

Amgen

Mirati Therapeutics

KRAS G12C Inhibitors Segment by Type

Adagrasib

Fulzerasib

Garsorasib

Sotorasib

KRAS G12C Inhibitors Segment by Application

Hospital

Clinic

Others

KRAS G12C Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global KRAS G12C Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of KRAS G12C Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of KRAS G12C Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the KRAS G12C Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of KRAS G12C Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of KRAS G12C Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of KRAS G12C Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. KRAS G12C Inhibitors Industry Trends Table 2. KRAS G12C Inhibitors Industry Drivers Table 3. KRAS G12C Inhibitors Industry Opportunities and Challenges Table 4. KRAS G12C Inhibitors Industry Restraints Table 5. Global KRAS G12C Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global KRAS G12C Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global KRAS G12C Inhibitors Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global KRAS G12C Inhibitors Sales Market Share by Manufacturers Table 9. Global KRAS G12C Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global KRAS G12C Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global KRAS G12C Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global KRAS G12C Inhibitors Manufacturers, Product Type & Application Table 13. Global KRAS G12C Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global KRAS G12C Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Adagrasib Table 17. Major Manufacturers of Fulzerasib Table 18. Major Manufacturers of Garsorasib Table 19. Major Manufacturers of Sotorasib Table 20. Global KRAS G12C Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global KRAS G12C Inhibitors Sales by Type (2021-2026) & (K Units) Table 22. Global KRAS G12C Inhibitors Sales by Type (2027-2032) & (K Units) Table 23. Global KRAS G12C Inhibitors Sales Market Share by Type (2021-2026) Table 24. Global KRAS G12C Inhibitors Sales Market Share by Type (2027-2032) Table 25. Global KRAS G12C Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global KRAS G12C Inhibitors Revenue by Type (2021-2026) & (K Units) Table 27. Global KRAS G12C Inhibitors Revenue by Type (2027-2032) & (K Units) Table 28. Global KRAS G12C Inhibitors Revenue Market Share by Type (2021-2026) Table 29. Global KRAS G12C Inhibitors Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Others Table 33. Global KRAS G12C Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global KRAS G12C Inhibitors Sales by Application (2021-2026) & (K Units) Table 35. Global KRAS G12C Inhibitors Sales by Application (2027-2032) & (K Units) Table 36. Global KRAS G12C Inhibitors Sales Market Share by Application (2021-2026) Table 37. Global KRAS G12C Inhibitors Sales Market Share by Application (2027-2032) Table 38. Global KRAS G12C Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global KRAS G12C Inhibitors Revenue by Application (2021-2026) & (K Units) Table 40. Global KRAS G12C Inhibitors Revenue by Application (2027-2032) & (K Units) Table 41. Global KRAS G12C Inhibitors Revenue Market Share by Application (2021-2026) Table 42. Global KRAS G12C Inhibitors Revenue Market Share by Application (2027-2032) Table 43. Global KRAS G12C Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global KRAS G12C Inhibitors Sales by Region (2021-2026) & (K Units) Table 45. Global KRAS G12C Inhibitors Sales Market Share by Region (2021-2026) Table 46. Global KRAS G12C Inhibitors Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global KRAS G12C Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 48. North America KRAS G12C Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America KRAS G12C Inhibitors Sales by Country (2021-2026) & (K Units) Table 50. North America KRAS G12C Inhibitors Sales by Country (2027-2032) & (K Units) Table 51. Europe KRAS G12C Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe KRAS G12C Inhibitors Sales by Country (2021-2026) & (K Units) Table 53. Europe KRAS G12C Inhibitors Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific KRAS G12C Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific KRAS G12C Inhibitors Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific KRAS G12C Inhibitors Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa KRAS G12C Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa KRAS G12C Inhibitors Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa KRAS G12C Inhibitors Sales by Country (2027-2032) & (K Units) Table 60. Global KRAS G12C Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global KRAS G12C Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 62. Global KRAS G12C Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 63. Global KRAS G12C Inhibitors Revenue Market Share by Region (2021-2026) Table 64. Global KRAS G12C Inhibitors Revenue Market Share by Region (2027-2032) Table 65. Innovent Biologics, Inc. Company Information Table 66. Innovent Biologics, Inc. Business Overview Table 67. Innovent Biologics, Inc. KRAS G12C Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Innovent Biologics, Inc. KRAS G12C Inhibitors Product Portfolio Table 69. Innovent Biologics, Inc. Recent Development Table 70. Genfleet Therapeutics (Shanghai), Inc. Company Information Table 71. Genfleet Therapeutics (Shanghai), Inc. Business Overview Table 72. Genfleet Therapeutics (Shanghai), Inc. KRAS G12C Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Genfleet Therapeutics (Shanghai), Inc. KRAS G12C Inhibitors Product Portfolio Table 74. Genfleet Therapeutics (Shanghai), Inc. Recent Development Table 75. Amgen Company Information Table 76. Amgen Business Overview Table 77. Amgen KRAS G12C Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Amgen KRAS G12C Inhibitors Product Portfolio Table 79. Amgen Recent Development Table 80. Mirati Therapeutics Company Information Table 81. Mirati Therapeutics Business Overview Table 82. Mirati Therapeutics KRAS G12C Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Mirati Therapeutics KRAS G12C Inhibitors Product Portfolio Table 84. Mirati Therapeutics Recent Development Table 85. Key Raw Materials Table 86. Raw Materials Key Suppliers Table 87. KRAS G12C Inhibitors Distributors List Table 88. KRAS G12C Inhibitors Customers List Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. KRAS G12C Inhibitors Product Image Figure 2. Global KRAS G12C Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global KRAS G12C Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global KRAS G12C Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global KRAS G12C Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 KRAS G12C Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Adagrasib Image Figure 9. Fulzerasib Image Figure 10. Garsorasib Image Figure 11. Sotorasib Image Figure 12. Global KRAS G12C Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global KRAS G12C Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global KRAS G12C Inhibitors Sales Market Share by Type (2021-2032) Figure 15. Global KRAS G12C Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global KRAS G12C Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global KRAS G12C Inhibitors Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global KRAS G12C Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global KRAS G12C Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global KRAS G12C Inhibitors Sales Market Share by Application (2021-2032) Figure 24. Global KRAS G12C Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global KRAS G12C Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global KRAS G12C Inhibitors Revenue Market Share by Application (2021-2032) Figure 27. North America KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America KRAS G12C Inhibitors Sales Market Share by Country (2021-2032) Figure 29. U.S. KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe KRAS G12C Inhibitors Sales Market Share by Country (2021-2032) Figure 34. Germany KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific KRAS G12C Inhibitors Sales Market Share by Country (2021-2032) Figure 41. China KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa KRAS G12C Inhibitors Sales Market Share by Country (2021-2032) Figure 49. Brazil KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile KRAS G12C Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global KRAS G12C Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global KRAS G12C Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America KRAS G12C Inhibitors Revenue (2021-2032) & (US$ Million) Figure 60. North America KRAS G12C Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe KRAS G12C Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. Europe KRAS G12C Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific KRAS G12C Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific KRAS G12C Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa KRAS G12C Inhibitors Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa KRAS G12C Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. KRAS G12C Inhibitors Value Chain Figure 68. Manufacturing Cost Structure Figure 69. KRAS G12C Inhibitors Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Adagrasib
  • Fulzerasib
  • Garsorasib
  • Sotorasib
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Innovent Biologics, Inc.
  • Genfleet Therapeutics (Shanghai), Inc.
  • Amgen
  • Mirati Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global KRAS G12C Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global KRAS G12C Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global KRAS G12C Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global KRAS G12C Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global KRAS G12C Inhibitors Market Dynamics
  1. 2.1 KRAS G12C Inhibitors Industry Trends
  2. 2.2 KRAS G12C Inhibitors Industry Drivers
  3. 2.3 KRAS G12C Inhibitors Industry Opportunities and Challenges
  4. 2.4 KRAS G12C Inhibitors Industry Restraints
3 KRAS G12C Inhibitors Market by Manufacturers
  1. 3.1 Global KRAS G12C Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global KRAS G12C Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global KRAS G12C Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global KRAS G12C Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global KRAS G12C Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global KRAS G12C Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global KRAS G12C Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global KRAS G12C Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 KRAS G12C Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 KRAS G12C Inhibitors Tier 1, Tier 2, and Tier 3
4 KRAS G12C Inhibitors Market by Type
  1. 4.1 KRAS G12C Inhibitors Type Introduction
  2. 4.1.1 Adagrasib
  3. 4.1.2 Fulzerasib
  4. 4.1.3 Garsorasib
  5. 4.1.4 Sotorasib
  6. 4.2 Global KRAS G12C Inhibitors Sales by Type
  7. 4.2.1 Global KRAS G12C Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global KRAS G12C Inhibitors Sales by Type (2021-2032)
  9. 4.2.3 Global KRAS G12C Inhibitors Sales Market Share by Type (2021-2032)
  10. 4.3 Global KRAS G12C Inhibitors Revenue by Type
  11. 4.3.1 Global KRAS G12C Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global KRAS G12C Inhibitors Revenue by Type (2021-2032)
  13. 4.3.3 Global KRAS G12C Inhibitors Revenue Market Share by Type (2021-2032)
5 KRAS G12C Inhibitors Market by Application
  1. 5.1 KRAS G12C Inhibitors Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global KRAS G12C Inhibitors Sales by Application
  6. 5.2.1 Global KRAS G12C Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global KRAS G12C Inhibitors Sales by Application (2021-2032)
  8. 5.2.3 Global KRAS G12C Inhibitors Sales Market Share by Application (2021-2032)
  9. 5.3 Global KRAS G12C Inhibitors Revenue by Application
  10. 5.3.1 Global KRAS G12C Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global KRAS G12C Inhibitors Revenue by Application (2021-2032)
  12. 5.3.3 Global KRAS G12C Inhibitors Revenue Market Share by Application (2021-2032)
6 Global KRAS G12C Inhibitors Sales by Region
  1. 6.1 Global KRAS G12C Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global KRAS G12C Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global KRAS G12C Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global KRAS G12C Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America KRAS G12C Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America KRAS G12C Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe KRAS G12C Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe KRAS G12C Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific KRAS G12C Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific KRAS G12C Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa KRAS G12C Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa KRAS G12C Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global KRAS G12C Inhibitors Revenue by Region
  1. 7.1 Global KRAS G12C Inhibitors Revenue by Region
  2. 7.1.1 Global KRAS G12C Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global KRAS G12C Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global KRAS G12C Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global KRAS G12C Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America KRAS G12C Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America KRAS G12C Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe KRAS G12C Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe KRAS G12C Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific KRAS G12C Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific KRAS G12C Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa KRAS G12C Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa KRAS G12C Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Innovent Biologics, Inc.
  2. 8.1.1 Innovent Biologics, Inc. Company Information
  3. 8.1.2 Innovent Biologics, Inc. Business Overview
  4. 8.1.3 Innovent Biologics, Inc. KRAS G12C Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Innovent Biologics, Inc. KRAS G12C Inhibitors Product Portfolio
  6. 8.1.5 Innovent Biologics, Inc. Recent Developments
  7. 8.2 Genfleet Therapeutics (Shanghai), Inc.
  8. 8.2.1 Genfleet Therapeutics (Shanghai), Inc. Company Information
  9. 8.2.2 Genfleet Therapeutics (Shanghai), Inc. Business Overview
  10. 8.2.3 Genfleet Therapeutics (Shanghai), Inc. KRAS G12C Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Genfleet Therapeutics (Shanghai), Inc. KRAS G12C Inhibitors Product Portfolio
  12. 8.2.5 Genfleet Therapeutics (Shanghai), Inc. Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen KRAS G12C Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen KRAS G12C Inhibitors Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 Mirati Therapeutics
  20. 8.4.1 Mirati Therapeutics Company Information
  21. 8.4.2 Mirati Therapeutics Business Overview
  22. 8.4.3 Mirati Therapeutics KRAS G12C Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mirati Therapeutics KRAS G12C Inhibitors Product Portfolio
  24. 8.4.5 Mirati Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 KRAS G12C Inhibitors Value Chain Analysis
  2. 9.1.1 KRAS G12C Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 KRAS G12C Inhibitors Production Mode & Process
  6. 9.2 KRAS G12C Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 KRAS G12C Inhibitors Distributors
  9. 9.2.3 KRAS G12C Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst